focus -WSS

focus

author：Wikipedia 2025-09-07 17:17:46 - browse：36

A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.

The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.

Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： How the messy conversation about Dolly changed bioethics

explore

focus

WSS

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

FDA panel to weigh safety of artificial wombs for preterm births

Federal weight loss drug coverage is 30 years out of date

The struggle to figure out which patients 'deserve' Wegovy

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Apple is now the first public company to be valued at $3 trillion

AdventHealth escalates lawsuit against insurance vendor Multiplan

The cancer drug shortage isn’t new — and neither are the solutions

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

3 trends to watch in health tech's hiring outlook for 2024

Jerome Adams on the need for new antivirals for Covid

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Apple is now the first public company to be valued at $3 trillion

Why psychiatrists like me stop taking insurance

Wikipedia

Medicare to pay more for cardiac rehab in hospital outpatient clinics

AdventHealth escalates lawsuit against insurance vendor Multiplan

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

FDA weighs limits of animal data in assessing artificial wombs

Ahead of JPM, here's who's profiting most in health care

House panel takes first step toward fixing drug shortages

focus

explore

focus

knowledge